Author:
Farrow Norma E.,Holl Eda K.,Jung Jeanne,Gao Junheng,Jung Sin-Ho,Al-Rohil Rami N.,Selim Maria A.,Mosca Paul J.,Ollila David W.,Antonia Scott J.,Tyler Douglas S.,Nair Smita K.,Beasley Georgia M.
Funder
Society of Surgical Oncology
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Thomas DC, Han G, Leong SP, et al. Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival. Ann Surg Oncol. 2019;26:2254–62.
2. Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol. 2017;76:258–63.
3. Eggermont AMM, Dummer R. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. Eur J Cancer Oxford Engl 1990. 2017;86:101–5.
4. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–801.
5. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献